

R.N.I. No. 50798/1990  
Date of Publication 13th of Same Month  
Date of Posting 13-14 Same Month

POSTAL REGISTRATION NO. DL(S)-01/3200/2021-2023  
POSTED AT LPC DELHI RMS DELHI-110006



LET YOUR PATIENTS  
**WAKE UP TO NEW POSSIBILITIES**

**RYBELSUS<sup>®</sup>**  
semaglutide tablets

A GAME CHANGER. A LIFE CHANGER

THE WORLD'S FIRST AND ONLY  
**ORAL GLP-1 RA<sup>1</sup>**



AVAILABLE  
**NOW**



GLP-1 RA: Glucagon-like peptide-1 receptor agonist.

Reference: 1. RYBELSUS<sup>®</sup> (package insert). Plainsboro, NJ: Novo Nordisk Inc; April 2021.

Rybelsus is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

• As monotherapy when metformin is considered inappropriate due to intolerance or contraindications;

• In combination with other medicinal products for the treatment of diabetes.

For healthcare professionals only.

For full prescribing information, refer to package insert.

Rybelsus<sup>®</sup> and The Apis bull logo are register trademarks of Novo Nordisk A/S. Please refer latest summary of product characteristics for more details. For the use of a registered medical practitioner or a hospital or a laboratory only.  
To get information on the updated package insert please contact +91 80 4030 3200 or write to us at [INAgree@novonordisk.com](mailto:INAgree@novonordisk.com)

IN22RYB00046